Literature DB >> 32532456

Rhabdomyolysis.

Brian Michael I Cabral1, Sherida N Edding2, Juan P Portocarrero3, Edgar V Lerma4.   

Abstract

Rhabdomyolysis is caused by the breakdown and necrosis of muscle tissue and the release of intracellular content into the blood stream. There are multiple and diverse causes of rhabdomyolysis but central to the pathophysiology is the destruction of the sarcolemmal membrane and release of intracellular components into the systemic circulation. The clinical presentation may vary, ranging from an asymptomatic increase in serum levels of enzymes released from damaged muscles to worrisome conditions such as volume depletion, metabolic and electrolyte abnormalities, and acute kidney injury (AKI). The diagnosis is confirmed when the serum creatine kinase (CK) level is > 1000 U/L or at least 5x the upper limit of normal. Other important tests to request include serum myoglobin, urinalysis (to check for myoglobinuria), and a full metabolic panel including serum creatinine and electrolytes. Prompt recognition of rhabdomyolysis is important in order to allow for timely and appropriate treatment. A McMahon score, calculated on admission, of 6 or greater is predictive of AKI requiring renal replacement therapy. Treatment of the underlying cause of the muscle insult is the first component of rhabdomyolysis management. Early and aggressive fluid replacement using crystalloid solution is the cornerstone for preventing and treating AKI due to rhabdomyolysis. Electrolyte imbalances must be treated with standard medical management. There is, however, no established benefit of using mannitol or giving bicarbonate infusion. In general, the prognosis of rhabdomyolysis is excellent when treated early and aggressively.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32532456     DOI: 10.1016/j.disamonth.2020.101015

Source DB:  PubMed          Journal:  Dis Mon        ISSN: 0011-5029            Impact factor:   3.800


  25 in total

1.  Myotoxicity Induced by Antiepileptic Drugs: Could be a Rare but Serious Adverse Event?

Authors:  Antonio Siniscalchi; Scott Mintzer; Giovambattista De Sarro; Luca Gallelli
Journal:  Psychopharmacol Bull       Date:  2021-11-03

2.  Recurring Weakness in Rhabdomyolysis Following Pfizer-BioNTech Coronavirus Disease 2019 mRNA Vaccination.

Authors:  Motoya Kimura; Jun-Ichi Niwa; Manabu Doyu
Journal:  Vaccines (Basel)       Date:  2022-06-11

3.  Isolated severe rhabdomyolisis revealing COVID-19: case report.

Authors:  M Merbouh; G El Aidouni; J Serbource; L M Couprie; C Bernardoni; B Housni; M Monchi
Journal:  Oxf Med Case Reports       Date:  2022-05-23

4.  Rhabdomyolysis Possibly Triggered by Clozapine, Paliperidone, Hyponatremia, and Rapid Correction of Hyponatremia: A Case Report.

Authors:  Myriam Lemelin; Nicolas Gagnon; Emmanuelle Jacques; Philippe Sirois; Alexandrine Coulombe
Journal:  Can J Hosp Pharm       Date:  2022-04-04

5.  Earlier continuous renal replacement therapy is associated with reduced mortality in rhabdomyolysis patients.

Authors:  Xiayin Li; Ming Bai; Yan Yu; Feng Ma; Lijuan Zhao; Yajuan Li; Hao Wu; Lei Zhou; Shiren Sun
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

6.  MBD2 mediates renal cell apoptosis via activation of Tox4 during rhabdomyolysis-induced acute kidney injury.

Authors:  Tianshi Sun; Qing Liu; Yifan Wang; Youwen Deng; Dongshan Zhang
Journal:  J Cell Mol Med       Date:  2021-03-25       Impact factor: 5.310

7.  Systemic lupus erythematosus presenting as hyponatremia-associated rhabdomyolysis: A case report.

Authors:  In Hee Lee; Seong Cho; Dong Jik Ahn; Min-Kyung Kim
Journal:  Medicine (Baltimore)       Date:  2021-10-01       Impact factor: 1.889

8.  Rhabdomyolysis: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document.

Authors:  Lisa Kodadek; Samuel P Carmichael Ii; Anupamaa Seshadri; Abhijit Pathak; Jason Hoth; Rachel Appelbaum; Christopher P Michetti; Richard P Gonzalez
Journal:  Trauma Surg Acute Care Open       Date:  2022-01-27

9.  RIG-I, a novel DAMPs sensor for myoglobin activates NF-κB/caspase-3 signaling in CS-AKI model.

Authors:  Peng-Tao Wang; Ning Li; Xin-Yue Wang; Jia-Le Chen; Chen-Hao Geng; Zi-Quan Liu; Hao-Jun Fan; Qi Lv; Shi-Ke Hou; Yan-Hua Gong
Journal:  Mil Med Res       Date:  2021-06-21

10.  When Should Statins Be Stopped?

Authors:  Mário Bibi; Ana Ferro; Filipa Guimarães; Paulo Coelho; Inês Chora
Journal:  Eur J Case Rep Intern Med       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.